Effects of host‐directed therapies on the pathology of tuberculosis. Issue 5 (24th March 2020)

• Record Type: Journal Article
• Authors: Tsenova, Liana; Singhal, Amit
• Is Part Of: Journal of pathology. Volume 250:Issue 5(2020)
• Page Start: 636
• Page End: 646
• Publication Date: 2020-03-24
• Subjects: tuberculosis -- immunity -- pathology -- host‐directed therapy; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5407
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co‐evolved with the human immune system and utilizes multiple strategies to persist within infected cells, to hijack several immune mechanisms, and to cause severe pathology and tissue damage in the host. This delays the efficacy of current antibiotic therapy and contributes to the evolution of multi‐drug‐resistant strains. These challenges led to the development of the novel approach in TB treatment that involves therapeutic targeting of host immune response to control disease pathogenesis and pathogen growth, namely, host‐directed therapies (HDTs). Such HDT approaches can (1) enhance the effect of antibiotics, (2) shorten treatment duration for any clinical form of TB, (3) promote development of immunological memory that could protect against relapse, and (4) ameliorate the immunopathology including matrix destruction and fibrosis associated with TB. In this review we discuss TB‐HDT candidates shown to be of clinical relevance that thus could be developed to reduce pathology, tissue damage, and subsequent impairment of pulmonary function. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.